Heart :: GSK’s Arixtra for treatment of acute coronary syndromes approved in Europe
GlaxoSmithKline announced that the European Medicines Agency (EMEA) has authorised a new indication for its once-daily anticoagulant ARIXTRA? 2.5 mg (fondaparinux sodium) for the treatment of specific acute coronary syndromes (ACS).